Skip to main content

Frazier Life Sciences — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

46
Companies
$4.7B
Total invested
$121.7M
Avg. check
10
Industries
Biotechnology 22Health Care 15Therapeutics 11Medical 10Biopharma 7Pharmaceutical 6+4 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 46
GondolaBio
August 2024

GondolaBio researches, develops and manufactures pharmaceutical products.

Biotechnology · Palo Alto$300.0M Venture - Series Unknown
Crystalys Therapeutics
July 2026

Crystalys Therapeutics is a clinical-stage biopharmaceutical company that develops targeted therapies for gout and hyperuricemia.

Biopharma · San Diego$130.0M Series B
RQ Bio
June 2026

RQ Bio is a biotechnology company that develops medicine based on potent broad-spectrum mAbs to provide immunity to viral infections.

Biotechnology · London$112.5M Series A
Krystal Biotech
May 2023

Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..

Biopharma · Pittsburgh$160.0M Post-IPO Equity
cAMPfield Therapeutics
May 2026

cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions.

Biopharma · San Diego$180.0M Series A
Sidewinder Therapeutics
April 2026

Sidewinder Therapeutics is a biotechnology company that offers life-saving therapies for cancer and rare diseases.

Biotechnology · San Diego$137.0M Series B
Trevi Therapeutics
April 2026

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

Biotechnology · Sandy Hook$173.0M Post-IPO Equity
Attovia Therapeutics
April 2025

Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.

Biotechnology · San Carlos$90.0M Series C
Vor Biopharma
March 2026

Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.

Biotechnology · Cambridge$75.0M Post-IPO Equity
Hillstar Bio
March 2025

Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.

Biotechnology · Boston$67.0M Series A
Immutrin
March 2026

Immutrin is a biotech developing next‑generation antibody therapies to clear amyloid deposits and reverse amyloidosis.

Biotechnology · Cambridge$87.1M Series A
Vima Therapeutics
March 2026

Vima Therapeutics operates as a biotechnology company.

Biotechnology · Cambridge$40.0M Series A
Applied Therapeutics
February 2024

Applied Therapeutics uses drug-development approach to target molecules and pathways that has roles in fatal or debilitating diseases.

Biotechnology · New York$100.0M Post-IPO Equity
Sudo Biosciences
February 2024

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

Biopharma · Carmel$30.0M Series B
Enlaza Therapeutics
September 2025

Enlaza Therapeutics is a biotechnology research company.

Biopharma · La Jolla$15.0M Venture - Series Unknown
Halda Therapeutics
August 2024

Halda Therapeutics is a research-stage drug discovery company.

Biotechnology · New Haven$126.0M Series B
Bluejay Therapeutics
May 2024

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

Biotechnology · San Mateo$182.0M Series C
Lassen Therapeutics
December 2023

Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.

Biotechnology · San Diego$85.0M Series B
Radionetics Oncology
August 2023

Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.

Health Care · California City$52.5M Series A
AirNexis Therapeutics
January 2026

AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions.

Biotechnology · Palo Alto$200.0M Series A
Diagonal Therapeutics
January 2026

Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.

Biopharma · Watertown$125.0M Series B
Alesta Therapeutics
January 2025

Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic.

Biotechnology · Leiden$67.0M Series A
Immunovant
December 2025

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

Biopharma · New York$550.0M Post-IPO Equity
Braveheart Bio
November 2025

Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.

Biotechnology · San Francisco$185.0M Series A

Where Frazier Life Sciences invests

Biotechnology22
Health Care15
Therapeutics11
Medical10
Biopharma7
Pharmaceutical6

About Frazier Life Sciences's portfolio

How many companies has Frazier Life Sciences invested in?

Frazier Life Sciences has invested in 46 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Frazier Life Sciences invest in?

Frazier Life Sciences's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 10 different industry categories.

What is Frazier Life Sciences's largest investment?

Among tracked funding rounds, Immunovant received $550.0M in a Post-IPO Equity round. Frazier Life Sciences's total known invested capital is $4.7B.

What is the average investment size for Frazier Life Sciences?

Frazier Life Sciences's average investment size is $121.7M across its portfolio of 46 companies.

What are Frazier Life Sciences's most recent investments?

Recent Frazier Life Sciences portfolio additions include GondolaBio, Crystalys Therapeutics, RQ Bio, Krystal Biotech, cAMPfield Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 46 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →